A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201

Phase 1

Not yet recruiting

• Conditions: Gastro-Intestinal Disorder
• Interventions: Drug: UI059; Drug: UIC202201

• Registration Number: NCT06393881
• Lead Sponsor: Korea United Pharm. Inc.

Brief Summary

A randomized, open-label, multiple-dose crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult volunteers

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-04
• Study First Submitted: 2024-04-28
• Study First Submitted QC: 2024-04-28
• Last Update Submitted: 2024-04-28
• Study First Posted: 2024-05-01
• Last Update Posted: 2024-05-01
• Study Start: 2024-07-03
• Primary Completion: 2024-09-14
• Study Completion: 2024-09-21

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• healthy adult volunteers aged 19 and above.
• For males, a weight of 50.0 kg or more, and for females, a weight of 45.0 kg or more, with a body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2.

BMI(kg/m2)=Weight(kg)/height(m)2

• No congenital or chronic diseases requiring treatment, and no pathological symptoms or findings based on internal medicine examination.
• Those who were determined to be suitable subjects for clinical trials as a result of tests such as clinical laboratory tests, vital signs, physical examination (physical examination), and 12-lead electrocardiogram
• Negative for H. pylori antibodies
• After receiving detailed explanations about the clinical trial and fully understanding, participants voluntarily decide to participate and provide written consent to adhere to the subject compliance requirements throughout the trial period.

Exclusion Criteria

• Current or past medical history of clinically significant conditions involving the liver, kidneys, nervous system, mental health, respiratory system, endocrine system, blood disorders, tumors, genitourinary system, cardiovascular system, digestive system, musculoskeletal system, etc., and in addition:

  • currently receiving antiretroviral drugs (rilpivirine, atazanavir, nelfinavir)
  • liver disorders
  • kidney disorders

• History of gastrointestinal conditions (Crohn's disease, ulcers, acute or chronic pancreatitis) or gastrointestinal surgery (excluding simple appendectomy or hernia repair) that may affect the absorption of the investigational drug.

• Pregnant (positive Urine-HCG) or lactating for female participants

• Have a history of hypersensitivity reactions (such as anaphylaxis or angioedema) or clinically significant hypersensitivity reactions to drugs, excipients, or other substances, including medications containing the active ingredients of the investigational drug, additives, and other drugs (such as aspirin, penicillin antibiotics, macrolide antibiotics).

• Have clinically significant findings on the 12-lead electrocardiogram during screening, including:

  • QTc interval > 450 ms for males or > 470 ms for females.
  • PR interval > 200 ms.
  • QRS duration > 120 ms.

• Showing the following results in clinical trial laboratory tests during screening:

  • liver function assessment: AST, ALT, ALP, γ-GTP, and total bilirubin exceeding twice the upper limit of the normal range.
  • Blood creatinine levels outside the reference range or calculated estimated glomerular filtration rate (eGFR) using the CKD-EPI formula less than 60 mL/min/1.73m2.

• History of drug abuse or individuals who have shown a positive reaction for abused substances in a urine drug test.

• During screening, exhibit vital signs measured after at least 3 minutes of rest in a seated position with systolic blood pressure (SBP) ≥ 150 mmHg or ≤ 90 mmHg, diastolic blood pressure (DBP) ≥ 100 mmHg or ≤ 60 mmHg, or a heart rate (HR) ≤ 40 bpm or ≥ 100 bpm.

• Have an abnormal diet that could affect the absorption, distribution, metabolism, or excretion of the investigational drug, or individuals who consume foods that could impact drug metabolism.

• Administered any prescription medications or herbal products that could influence the characteristics of the investigational drug within 2 weeks before the first dose or any OTC drugs or vitamin supplements within 10 days before the first dose. (If there is no effect on the pharmacokinetic properties of this investigational drug, the investigator may participate in the clinical trial at the discretion of the investigator.)

• Administer drugs that induce or inhibit drug-metabolizing enzymes, such as barbiturates, within 1 month before the first administration date.

• Participated in other clinical trials within 6 months prior to the first administration date (The endpoint for determining the end of participation in another clinical trial is considered one day after the last administration in that trial.)

• Those who have consistently consumed alcohol in excess of 21 units/week (1 unit = 10 g = 12.5 mL of pure alcohol) within 6 months prior to the first administration date or who are unable to abstain from alcohol from the time of written consent to the time of PSV.

• Smokers who smoke more than 10 cigarettes on average per day within 3 months before the first administration date and those who are unable to quit smoking from 24 hours before each administration until the time of the last blood collection

• Consumed food containing grapefruit or cannot refrain from eating it from 48 hours before the first administration until the time of PSV

• Those who consumed caffeine-containing foods (coffee, green tea, black tea, carbonated drinks, coffee milk, tonic drinks, etc.) during the period from 24 hours before administration to the time of the last blood collection, or who cannot refrain from consuming them.

• Those who engaged in vigorous exercise exceeding the level of daily life during the period from 48 hours before the first administration to the time of PSV, or who cannot refrain from vigorous exercise

• From the time of the subject's written consent until 2 weeks after the last administration of the investigational drug, even if the person, spouse, or partner is planning to become pregnant or is not planning to become pregnant, a recognized method of contraception (e.g., administration of contraceptives, implantation or intrauterine device, sterilization procedure (vasectomy), not using surgical resection, tubal ligation, etc.) or blocking methods (combined use of spermicides, condoms, contraceptive diaphragms, vaginal sponges, or cervical caps)

• Judged by the investigator to be unsuitable for participation in clinical trials due to reasons other than the above selection/exclusion criteria

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
UI059	UI059	-
UIC202201	UIC202201	-

Primary Outcome Measures

Name	Time	Method
Percent decrease from baseline in integrated gastric acidity	Day -1~Day 1, Day 1~Day 2, Day 7	Percent decrease from baseline in integrated gastric acidity for 24 hours after multiple(7th dose) administrations
AUCtau,ss	Day 1: 0~24hours / Day 5, 6: 0hours / Day 7: 0~24hours	Area under the plasma concentration-time curve within a dosing interval at steady state

Trial Locations

Locations (1)

Chungbuk national university hospital; 🇰🇷 Cheongju-si, Chungcheongbuk-do, Korea, Republic of